Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metabolic Dysfunction Associated Steatotic Liver Disease: early-phase trial registry
5 of 8 indexed Metabolic Dysfunction Associated Steatotic Liver Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Metabolic Dysfunction Associated Steatotic Liver Disease: 8 US clinical trials tracked, 5 recruiting.
Metabolic Dysfunction Associated Steatotic Liver Disease is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Merck Sharp & Dohme, running 2 of these trials.
Enrollment posture brief
Registry condition metabolic-dysfunction-associated-steatotic-liver-disease
OPEN 5 | RECR 63% | LATE 1 | EARLY 2 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
Metabolic Dysfunction Associated Steatotic Liver Disease lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metabolic Dysfunction Associated Steatotic Liver Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metabolic Dysfunction Associated Steatotic Liver Disease is recruiting above its size-band peers.
5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metabolic Dysfunction Associated Steatotic Liver Disease research.
Merck Sharp & Dohme accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Metabolic Dysfunction Associated Steatotic Liver Disease enrolment sits around 124 participants.
Median target enrolment is 124 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.
-
Metabolic Dysfunction Associated Steatotic Liver Disease research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company
NCT07165028
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
Emory University
NCT06218589
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Pichamol Jirapinyo, MD, MPH
NCT06138821
Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
Seoul National University Hospital
NCT07192159
Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis
University of Alabama at Birmingham
NCT06735924
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Merck Sharp & Dohme
NCT06465186
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
Baylor College of Medicine
NCT06854185
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Merck Sharp & Dohme
NCT06482112
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metabolic Dysfunction Associated Steatotic Liver Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metabolic Dysfunction Associated Steatotic Liver Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metabolic Dysfunction Associated Steatotic Liver Disease page
8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Metabolic Dysfunction Associated Steatotic Liver Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Merck Sharp & Dohme sponsors the most Metabolic Dysfunction Associated Steatotic Liver Disease trials on record, review their full trial history before evaluating a specific study. See Merck Sharp & Dohme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metabolic Dysfunction Associated Steatotic Liver Disease condition card totals 8 registered trials; most-linked intervention Efinopegdutide; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.